Form 6-K Sanofi For: Sep 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/7/2026
- US stocks close down as oil spikes 12%, job market weakens
- U.S. nonfarm payroll employment unexpectedly falls in February
- Oracle stock falls on report of scrapped Texas data center plans
- Kuwait cuts oil output as storage fills up
- Boeing reportedly nearing 500-aircraft deal with China ahead of Trump visit
- After-hours movers: Marvell, Samsara, GAP, Cooper Cos.
- After-hours movers: Broadcom, StubHub, Cracker Barrel, Grocery Outlet, Veeva Systems and more
- After-hours movers: Moderna, CrowdStrike, Ross Stores, Box and more
- After-hours movers: MongoDB, Credo, SoFi Technologies and more
- After-hours movers: Dell, Block, CoreWeave, Autodesk, MARA and more
William Blair on Sanofi (SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'
September 4, 2025 10:03 AM UTCWilliam Blair on Sanofi (NASDAQ: SNY): 'We believe it will be important to see the efficacy broken out by prior advanced therapy'.
The analyst comments "On Thursday, September 4, Sanofi (SNY $49.89) reported the top-line results for the anti-OX40 ligand (OX40L) antibody amlitelimab in atopic dermatitis (AD) from the Phase III COAST 1 trial in a press release. The release included numerical results for the key efficacy endpoints, and full detailed results will be presented at a later... More
